Stempeutics Receives Advanced Therapy Medicinal Product (ATMP)...

The ATMP classification, approved by the committee for Advanced Therapies of the European Medicines Agency, will allow Stempeutics to commercialize the product 'Stempeucel' across the European Union region. Thromboangiitis Obliterans is a recurring progressive inflammation and thrombosis of small and medium arteries and veins of the feet.

http://ift.tt/1HqwESM